Cost-effectiveness analysis of humanitarian relief interventions: visceral leishmaniasis treatment in the Sudan
- PMID: 10351471
- DOI: 10.1093/heapol/14.1.70
Cost-effectiveness analysis of humanitarian relief interventions: visceral leishmaniasis treatment in the Sudan
Abstract
Spending by aid agencies on emergencies has quadrupled over the last decade, to over US$6 billion. To date, cost-effectiveness has seldom been considered in the prioritization and evaluation of emergency interventions. The sheer volume of resources spent on humanitarian aid and the chronicity of many humanitarian interventions call for more attention to be paid to the issue of 'value for money'. In this paper we present data from a major humanitarian crisis, an epidemic of visceral leishmaniasis (VL) in war-torn Sudan. The special circumstances provided us, in retrospect, with unusually accurate data on excess mortality, costs of the intervention and its effects, thus allowing us to express cost-effectiveness as the cost per Disability Adjusted Life Year (DALY) averted. The cost-effectiveness ratio, of US$18.40 per DALY (uncertainty range between US$13.53 and US$27.63), places the treatment of VL in Sudan among health interventions considered 'very good value for money' (interventions of less than US$25 per DALY). We discuss the usefulness of this analysis to the internal management of the VL programme, the procurement of funds for the programme, and more generally, to priority setting in humanitarian relief interventions. We feel that in evaluations of emergency interventions attempts could be made more often to perform cost-effectiveness analyses, including the use of DALYs, provided that the outcomes of these analyses are seen in the broad context of the emergency situation and its consequences on the affected population. This paper provides a first contribution to what is hoped to become an international database of cost-effectiveness studies of health interventions during relief operations, which use a comparable measure of health outcome such as the DALY.
PIP: With spending by official aid agencies upon emergencies quadrupling over the past decade to more than US$6 billion, greater attention needs to be paid to the cost-effectiveness of the humanitarian interventions funded by such agencies. Data are presented from an epidemic of visceral leishmaniasis (VL) in civil war-torn Sudan, in a study of how such data could have been used in planning relevant health interventions. Data are available on the impact of a VL treatment program for 3067 patients between August 1990 and July 1991. Calculations made with the available data and relevant assumptions yielded a cost-effectiveness ratio of US$18.40 per Disability Adjusted Life Year (DALY), with an uncertainty range of US$13.53-27.63, a highly cost-effective health intervention. The applicability of the analysis to the internal management of the VL program, the procurement of funds for the program, and to priority setting in humanitarian relief interventions are discussed. When evaluating emergency interventions, efforts could be made more often to perform cost-effectiveness analyses, including the use of DALYs, provided that the outcomes of the analyses are seen in the broad context of the emergency situation and its consequences upon the affected population.
Similar articles
-
Royal Society of Tropical Medicine and Hygiene joint meeting with Médecins Sans Frontières at Manson House, London, 20 March 2003: field research in humanitarian medical programmes. Médecins Sans Frontières interventions against kala-azar in the Sudan, 1989-2003.Trans R Soc Trop Med Hyg. 2003 Nov-Dec;97(6):609-13. doi: 10.1016/s0035-9203(03)80047-0. Trans R Soc Trop Med Hyg. 2003. PMID: 16134257
-
The epidemic of visceral leishmaniasis in western Upper Nile, southern Sudan: course and impact from 1984 to 1994.Int J Epidemiol. 1996 Aug;25(4):862-71. doi: 10.1093/ije/25.4.862. Int J Epidemiol. 1996. PMID: 8921468
-
Pneumonia Prevention during a Humanitarian Emergency: Cost-effectiveness of Haemophilus Influenzae Type B Conjugate Vaccine and Pneumococcal Conjugate Vaccine in Somalia.Prehosp Disaster Med. 2015 Aug;30(4):402-11. doi: 10.1017/S1049023X15004781. Epub 2015 Jun 10. Prehosp Disaster Med. 2015. PMID: 26061190
-
Breastfeeding promotion and priority setting in health.Health Policy Plan. 1996 Jun;11(2):156-68. doi: 10.1093/heapol/11.2.156. Health Policy Plan. 1996. PMID: 10158457 Review.
-
Examining the use of economic evaluations in health-related humanitarian programmes in low- and middle-income countries: a systematic review.Health Policy Plan. 2020 Mar 1;35(2):210-218. doi: 10.1093/heapol/czz144. Health Policy Plan. 2020. PMID: 31697373
Cited by
-
Emerging therapeutic targets for treatment of leishmaniasis.Expert Opin Ther Targets. 2018 Jun;22(6):467-486. doi: 10.1080/14728222.2018.1472241. Epub 2018 May 9. Expert Opin Ther Targets. 2018. PMID: 29718739 Free PMC article. Review.
-
Health economic evaluations of visceral leishmaniasis treatments: a systematic review.PLoS Negl Trop Dis. 2015 Feb 27;9(2):e0003527. doi: 10.1371/journal.pntd.0003527. eCollection 2015 Feb. PLoS Negl Trop Dis. 2015. PMID: 25723482 Free PMC article.
-
Treating cutaneous leishmaniasis patients in Kabul, Afghanistan: cost-effectiveness of an operational program in a complex emergency setting.BMC Infect Dis. 2007 Jan 30;7:3. doi: 10.1186/1471-2334-7-3. BMC Infect Dis. 2007. PMID: 17263879 Free PMC article.
-
Assessing the cost-effectiveness of interventions within a humanitarian organisation.Disasters. 2019 Jul;43(3):575-590. doi: 10.1111/disa.12344. Epub 2019 Apr 22. Disasters. 2019. PMID: 31012136 Free PMC article.
-
Immunogenicity of HLA-DR1 Restricted Peptides Derived from Leishmania major gp63 Using FVB/N-DR1 Transgenic Mouse Model.Iran J Parasitol. 2013 Apr;8(2):273-9. Iran J Parasitol. 2013. PMID: 23914241 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous